Overview


According to FutureWise analysis the market for in vitro diagnostics in 2023 is US$ 121.38 billion, and is expected to reach US$ 176.89 billion by 2031 at a CAGR of 4.82%.

Technological advancements in in-vitro diagnostic techniques have contributed to the global in-vitro diagnostics market growth. With the assistance of key players in launching advanced in-vitro diagnostic tools, the market for these products will most likely see much growth. For instance, Qiagen, which is a company that ranks as one of the prominent providers of point of care molecular diagnostics, provides the highest record of accurate results for particularized patient treatments. Moreover, the government officiated the healthcare system and other organizations have had a positive effect on market growth. Owing to government programs, there has been significant education and information regarding IVD tools and personalized medication and treatment. All these factors have served as the basis for lucrative business opportunities. Thus, the exorbitant costs of in-vitro treatment may pose potential problems in the progress during the forecast time frame.

The market is expected to see a boost in the demand for in-vitro diagnostic kits and reagents. Major players are looking to develop highly innovative kits for an accurate diagnosis. There is a demand for software in diagnostic devices and tools by medical professionals. Also, there has also been a need for it in terms of diagnosing various chronic diseases. By technology, the market has been divided into applications related to clinical chemistry. This clinical chemistry includes diagnosing blood glucose levels and detection of hormone fluctuations. Application-wise, alarming levels of ailments in cardiovascular diseases include stroke, arrhythmia and coronary artery disease is expected to spurn the demand for in-vitro diagnostic treatments. Based on the end-user, point of care diagnostic examinations includes pregnancy kits, glucose meters and biosensors that will deliver fast results. Observing the segmentation by region, North America and the Asia Pacific have been predicted to hold the largest global in-vitro diagnostics market share. A rise in diseases, as well as growing awareness in the public arena, has propelled much considerable growth in the region of North America. In the Asia Pacific region, shifts in healthcare reforms and healthcare expenditure is registered to boost regional business growth. While the market for in-vitro consists of many major players, there are smaller to midsize companies as well who are making their presence felt in the market by adopting technological changes and improvements in their products. These strategies are carried out by launching products at a much lower price.

  • Siemens Healthcare
  • Abbott Laboratories
  • Qiagen N.V.
  • Thermo Fischer Scientific Inc
  • F.Hoffmann-La Roche AG
  • Danaher Corporation
  • Sysmex Corporation
  • Becton, Dickinson and Company
  • Biomerieux SA
  • Bio-rad Laboratories Inc
  • Johnson and Johnson
  • Agilent Technologies
  • Diasorin
  • Leica Biosystems Nussloch GmbH
  • Cepheid
  • Caris Life Science Inc
  • Merck KGaA
  • Accelerate Diagnostics Inc
  • GENSPEED Biotech GmbH
  • SpeeDx Pty Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product and Services

  • Reagents & Kits
  • Instruments
    • Fully-automated Instruments
    • Semi-automated Instruments
    • Others
  • Data Management Software
  • Services

By Technology

  • Immunochemistry/Immunoassay
    • Chemiluminescence Immunoassay (CLIA)
    • Fluorescence Immunoassay (FIA)
    • Colorimetric Immunoassay (CI)
    • Radioimmunoassays (RIA)
    • Rapid Tests
    • Western Blot
    • ELISPOT
  • Clinical Chemistry
    • Basic Metabolic Panel
    • Electrolyte Panel
    • Liver Panel
    • Lipid Profile
    • Renal Profile
    • Thyroid Function Panel
    • Specialty Chemicals
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • In-situ Hybridization
    • DNA Microarrays
    • Others
  • Hemostasis
  • Urinalysis
  • Others

By Application

  • Infectious Diseases
  • Diabetes
  • Drug Testing/Pharmacogenomics
  • Autoimmune Diseases
  • Oncology
  • Cardiology
  • HIV/AIDS
  • Nephrology
  • Other Applications

By End User

  • Laboratories
    • Large/Reference Laboratories
    • Medium-sized Laboratories
    • Small Laboratories
  • Hospitals
  • Academics
  • Point-Of-Care Testing
  • Patient Self-Testing
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the In-vitro Diagnostics Market By Product And Services, By Technology, By Application, By End-user and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record evaluate and competitive landscape mapping-product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   In Vitro Diagnostics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of In Vitro Diagnostics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   In Vitro Diagnostics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   In Vitro Diagnostics Market, By Product and Services Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Reagents & kits
        2. Instruments
         2.1. Fully-automated Instruments
         2.2. Semi-automated Instruments
         2.3. Others
        3. Data Management Software
        4. Services

  • 8.   In Vitro Diagnostics Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Immunochemistry/Immunoassay
         1.1. Chemiluminescence Immunoassay (CLIA)
         1.2. Fluorescence Immunoassay (FIA)
         1.3. Colorimetric Immunoassay (CI)
         1.4. Radioimmunoassays (RIA)
         1.5. Rapid Tests
         1.6. Western Blot
         1.7. ELISPOT
        2. Clinical Chemistry
         2.1. Basic Metabolic Panel
         2.2. Electrolyte Panel
         2.3. Liver Panel
         2.4. Lipid Profile
         2.5. Renal Profile
         2.6. Thyroid Function Panel
         2.7. Specialty Chemicals
        3. Molecular Diagnostics
         3.1. Polymerase Chain Reaction (PCR)
         3.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
         3.3. In-situ Hybridization
         3.4. DNA Microarrays
         3.5. Others
        4. Hemostasis
        5. Urinalysis
        6. Others

  • 9.   In Vitro Diagnostics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Infectious Diseases
        2. Diabetes
        3. Drug Testing/Pharmacogenomics
        4. Autoimmune Diseases
        5. Oncoloy
        6. Cardiology
        7. HIV/AIDS
        8. Nephrology
        9. Other Applications

  • 10.   In Vitro Diagnostics Market, By End-user Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Laboratories
         1.1. Large/Reference Laboratories
         1.2. Medium-sized Laboratories
         1.3. Small Laboratories
        2. Hospitals
        3. Academics
        4. Point-Of-Care Testing
        5. Patient Self-Testing
        6. Others

  • 11.   North America In Vitro Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America In Vitro Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe In Vitro Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific In Vitro Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Siemens Healthcare
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Abbott Laboratories
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Qiagen N.V.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Thermo Fischer Scientific Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. F.Hoffmann-La Roche AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Danaher Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sysmex Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Becton, Dickinson and Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Biomerieux SA
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Bio-rad Laboratories Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Johnson and Johnson
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Agilent Technologies
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Diasorin
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Leica Biosystems Nussloch GmbH
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Cepheid
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Caris Life Science Inc
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Merck KGaA 
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Accelerate Diagnostics Inc
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. GENSPEED Biotech GmbH
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. SpeeDx Pty Ltd
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients